metastatic colorectal cancer (mCRC)
Showing 26 - 50 of >10,000
First Line Treatment for BRAFV600E Mutant Metastatic Colorectal
Completed
- BRAF V600E Mutation Positive
- Metastatic Colorectal Cancer
- Non Interventional study
-
St. Veit/Glan, Austria
- +33 more
Jan 20, 2023
Metastatic Colorectal Cancer Trial in United States (Rivoceranib, Trifluridine/Tipiracil)
Active, not recruiting
- Metastatic Colorectal Cancer
-
Sarasota, Florida
- +3 more
May 18, 2022
Metastatic Colorectal Cancer Trial in Nanjing (Envafolimab, Trifluridine/Tipiracil, Bevacizumab)
Recruiting
- Metastatic Colorectal Cancer
- Envafolimab
- +2 more
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Sep 24, 2023
Colorectal Cancer Trial in Philadelphia (Regorafenib, 5-FU, Leucovorin)
Terminated
- Colorectal Cancer
- Regorafenib
- +2 more
-
Philadelphia, PennsylvaniaFox Chase Cancer Center
Jan 10, 2022
Fruquintinib in the Cross-line Treatment of Refractory mCRC
Recruiting
- Fruquintinib
- Metastatic Colorectal Cancer
- Fruquintinib+PD-1 inhibitors
- Fruquintinib+TAS-102
-
Wuhan, Hubei, China
- +2 more
Oct 23, 2023
Metastatic Colorectal Cancer Trial in Taoyuan (TSB-9-W1)
Completed
- Metastatic Colorectal Cancer
-
Taoyuan, TaiwanChang Gung Medical Foundation
Mar 21, 2022
Advanced Metastatic Colorectal Cancer Trial in Hangzhou (Raltitrexed, Irinotecan, Bevacizumab)
Recruiting
- Advanced Metastatic Colorectal Cancer
- Raltitrexed
- +3 more
-
Hangzhou, Zhejiang, Chinathe Second Affiliated Hospital of Medical College of Zhejiang Un
Dec 22, 2021
Metastatic Colorectal Cancer. Real-World Data Analysis.
Completed
- Metastatic Colorectal Cancer
-
Istanbul, TurkeyIstanbul Medeniyet University Hospital
Oct 25, 2021
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With
Completed
- Metastatic Colorectal Adenocarcinoma
- Fruquintinib
- +3 more
-
Changsha, Hunan, ChinaHunan Cancer hospital
Sep 2, 2023
Metastatic Colorectal Cancer, mCRC Trial in Guangzhou (Tislelizumab & Fruquintinib)
Not yet recruiting
- Metastatic Colorectal Cancer
- mCRC
- Tislelizumab & Fruquintinib
-
Guangzhou, Guangdong, China
- +1 more
Jan 25, 2023
Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece
Completed
- Metastatic Colorectal Cancer
-
Heraklion, Crete, Greece
- +7 more
Mar 4, 2022
Metastatic Colorectal Cancer Trial in Milan (Temozolomide, Nivolumab, Ipilimumab)
Completed
- Metastatic Colorectal Cancer
- Temozolomide
- +2 more
-
Milan, MI, ItalyFondazione IRCCS Istituto Nazionale dei Tumori
Apr 1, 2022
Regorafenib in Taiwan Metastatic Colorectal Cancer Patients
Completed
- Metastatic Colorectal Cancer
-
Taipei, TaiwanTaipei Veterans General Hospital
Jul 21, 2021
Metastatic Colorectal Cancer Trial in Madison (Panitumumab, Cetuximab, Irinotecan)
Recruiting
- Metastatic Colorectal Cancer
- Panitumumab
- +2 more
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
Sep 13, 2022
Metastatic Colorectal Cancer Trial in Wuhan (SBRT, Fruquintinib, Cadonilimab)
Not yet recruiting
- Metastatic Colorectal Cancer
- SBRT, Fruquintinib, Cadonilimab
-
Wuhan, Hubei, ChinaCancer Center, Union Hospital, Tongji Medical College, Huazhong
Feb 18, 2023
Metastatic Colorectal Cancer Trial in Denmark, Germany, Spain (FOLFIRI Protocol, SCO-101)
Recruiting
- Metastatic Colorectal Cancer
- FOLFIRI Protocol
- SCO-101
-
Aalborg, Denmark
- +11 more
Feb 28, 2022
Advanced or Metastatic Colorectal Cancer (mCRC) Trial (CA102N)
Available
- Advanced or Metastatic Colorectal Cancer (mCRC)
- (no location specified)
Mar 2, 2022
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma Trial in Houston (CXCR1/2
Recruiting
- Metastatic Colon Adenocarcinoma
- +20 more
- CXCR1/2 Inhibitor SX-682
- Nivolumab
-
Houston, TexasM D Anderson Cancer Center
Aug 17, 2022
Metastatic Colorectal Cancer Trial in Wuhan (SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab)
Recruiting
- Metastatic Colorectal Cancer
- SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab
-
Wuhan, Hubei, ChinaXianglin Yuan
Jun 24, 2022
NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma Trial in Pittsburgh (Pixatimod, Nivolumab, Cyclophosphamide (low
Recruiting
- NSCLC
- +2 more
- Pixatimod
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Mar 28, 2022
New Prognostic Score for Adult RAS Wild-type mCRC Treated With
Active, not recruiting
- Metastatic Colorectal Cancer
- RAS Wild-type
-
Freiburg, Baden-Württemberg, GermanyPraxis für interdisziplinäre Onkologie & Hämatologie
Jul 29, 2022
Metastatic Colorectal Cancer Trial in Baltimore (CY, GVAX, SGI-110)
Completed
- Metastatic Colorectal Cancer
- CY
- +2 more
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mar 26, 2021